22 June 2010 4:17 PM+ 7 ( 13 days ago) Discuss  | Bury | Tagged: bristol myers squibb
LOS ANGELES (Reuters) Bristol-Myers Squibb Co will pay another $17 million to end its development collaboration for Exelixis Inc's experimental cancer drug XL184.Exelixis said on Sunday it will continue to develop the drug, which is being stud...
bristol myers squibb
To comment or read full article login. No account? Register free.

No one has commented on this article yet.